Background IL-1b is a cytokine involved in mediating epithelial barrier dysfunction in the gut. It is known that IL1b mediates activation of non-muscle myosin light chain kinase in epithelial cells, but the precise mechanism by which epithelial barrier dysfunction is induced by IL-1b is not understood.
Introduction
Gut barrier dysfunction is a significant factor in the development of several disease conditions including Crohn's disease (CD), ulcerative colitis, inflammatory bowel disease, and trauma-induced hyperpermeability of the gut. Since gut barrier function is largely maintained by epithelial tight junctions (TJ) lining the intestinal wall, an intense area of study has focused on identifying mechanisms surrounding homeostasis of the gut epithelial barrier [1, [19] [20] [21] . Specifically, it has been reported that intestinal inflammation in a mouse model for inflammatory bowel disease was preceded by hyperpermeability of the gut epithelium [14] and that restoring epithelial tight junctions attenuated the development of enterocolitis [3] . This suggested that a breach in tight junction integrity not only represents a cause of inflammation, but is also etiologically important.
A major regulatory event leading to increased paracellular permeability involves the phosphorylation of myosin light chain (MLC) by non-muscle myosin light chain kinase (nmMLCK) [29] . nmMLCK is a calcium calmodulin-dependent serine/threonine kinase that regulates actin/myosin reorganization and cell contraction in response to various stimuli that mediate short-term contractile events (thrombin, histamine, etc.) as well as mediators of chronic alterations in intestinal permeability (TNFa, IL-1b). Three MLCK isoforms are known: a non-muscle isoform (210 kDa), a short smooth muscle form (108 kDa), and the non-enzymatic protein telokin (21 kDa) . nmMLCK is primarily expressed in endothelial cells, epithelial cells, and neutrophils [6, 29, 30, 32] and is involved in the regulatory mechanisms surrounding inflammation-mediated permeability of the gut. For example, MLCK activation plays a significant role in microvascular hyperpermeability induced by neutrophil stimulation or thermal injury [10, 25, 32, 33] . In addition, nmMLCK is essential to sodium nutrient cotransport and TNFa-induced intestinal epithelial barrier loss and mucosal damage [13] . Transgenic mice with the nmMLCK isoform deleted showed both endothelial and epithelial barrier property enhancement in the gut, as well as attenuation of burn-induced vascular leakage [25] .
IL-1b has been shown to play a significant role in intestinal inflammation resulting from inflammatory bowel disease (IBD) [24] . Patients with CD often present elevated IL-1b due to insufficient production of an endogenous IL-1R antagonist [18] . Although it has been demonstrated that IL-1b not only plays a role in intestinal inflammation but also contributes to increased permeability across the epithelial barrier in the gut, the precise mechanism of tight junction disruption is unclear. Tight junctions are composed of several types of proteins including ZO-1, occludin, JAM, and the claudin family of proteins. Claudin-3 plays a particularly essential role in intestinal epithelial barrier function [15, 17, 22] . It has been shown that claudin-3 expression is positively correlated with epithelial tightness [23] , and that disruption of claudin-3 expression negatively affects epithelial barrier function [9] . To the best of our knowledge, the role of IL-1b signaling on claudin-3 expression in intestinal epithelial cells has not been reported.
Claudin-3 expression is regulated in a number of ways, one of which is through transcriptional modulation by the dual function protein, b-catenin [12] . Upon stimulation with inflammatory factors, b-catenin phosphorylation occurs and may translocate to the nucleus where it associates with a number of transcription factors to regulate several genes, including claudin-3 [12] . However, the role of b-catenin-mediated transcriptional repression of tight junction proteins in epithelial cells resulting from IL-1b treatment has not been investigated.
It has been recently established that IL-1b signaling activates nmMLCK in endothelial and epithelial cells [2] . Inhibition of nmMLCK in endothelial and epithelial cells has restored barrier function in response to several inflammatory factors including IL-1b [2] . Furthermore, these experiments also showed that nmMLCK was required for IL-1b-induced b-catenin nuclear accumulation and FoxO1-mediated claudin downregulation in brain endothelial cells [4] . Given the critical role of claudin-3 and nmMLCK in epithelial barrier function, and that IL-1b is known to disrupt epithelial tight junction integrity, here we sought to determine whether nmMLCK plays a role in claudin-3 downregulation by promoting b-catenin association with the claudin-3 promoter in IL-1b-treated intestinal epithelial cells.
Methods
The following methods were utilized to investigate the objectives of this study.
Cell Culture
Caco2 cells were obtained from the American Type Culture Collection (ATCC) and cultured per ATCC guidelines. Prior to treatment with IL-1b, cells were serum starved overnight to promote G0 synchronization. Cell treatments (ML-7, IL-1b, Sigma) were dissolved in PBS ? 0.1 % BSA and then added to cell culture media at indicated concentrations. Vehicle control was diluent alone at the same volume as treatment. Cells were assayed for mRNA levels, protein localization, permeability coefficient, and monolayer resistance using the methods described below. Protein expression was assayed using standard Western blotting techniques.
Quantitative Real-Time PCR
Total RNA from Caco2 monolayers was harvested with RNAzol (Molecular Research Center) according to the manufacturer's protocol. RNA was reverse-transcribed using iScript cDNA Synthesis Kit (Bio-Rad, CA, USA) using 500 ng total RNA per 20 lL reaction. Wet laboratory validated primers (PrimePCR Assays; Bio-Rad, CA, USA) for the genes and reference gene (GAPDH) quantified in these studies were used. For real-time PCR, SsoAdvanced SYBR Green Supermix was used; RT-PCR was ran and analyzed on Bio-Rad CFX Connect (Bio-Rad, CA, USA) per manufacturer's instructions.
Chromatin Immunoprecipitation (ChIP) Assay
Chromatin immunoprecipitation (ChIP) assays were performed with chromatin isolated from Caco2 monolayers using an agarose ChIP kit (Pierce). Cells were treated with vehicle control (PBS ? 0.1 % BSA), IL-1b (100 ng/mL, Sigma), or ML-7 (10 lM, Sigma) ? IL-1b for 3 h. DNA was precipitated per standard procedures and amplified in standard qualitative PCR and qRT-PCR using oligonucleotides flanking the putative Cldn3 promoter region. Non-precipitated/input samples were used as positive controls. DCq was calculated by normalizing with Input.
Transepithelial Resistance (TER) Measurements
Caco2 barrier function was determined as previously described [26] by measuring cell-cell adhesive resistance Dig Dis Sci (2016) 61:2252-2261 2253 to electric current using an electric cell-substrate impedance sensing (ECIS) system (Applied Biophysics, Troy, NY). ECIS tracings expressed as transepithelial electrical resistance (TER) are normalized to baseline, and comparisons were made between IL-1b ([10 or 100 ng/mL])-and vehicle control ([0.1 % BSA in PBS])-treated Caco2 monolayers. TER changes were recorded every 90 s, and statistical analyses were performed at peak drop in IL-1b TER (n = 3; for three independent experiments).
Immunocytochemistry
Caco2 monolayers were grown in two-chamber slides (Nunc) for immunocytochemistry analysis. Since translocation of transcriptional factors temporally precedes gene regulation, detection of nuclear b-catenin detection was performed 3 h post-treatment ( Fig. 3 ), but the detection of claudin-3 and E-cadherin ( Fig. 4 ) was performed after IL1b-induced permeability changes were detected (24 h). In both sets of experiments, cells were treated with vehicle control (PBS ? 0.1 % BSA), IL-1b (100 ng/mL, Sigma), or ML-7 (10 lM, Sigma) ? IL-1b. Fixation and immunolabeling were performed using standard protocols. Briefly, cells were washed twice [PBS with 2 mM CaCl 2 , 2 mM Slides were mounted with anti-fade media containing DAPI (Life Technologies). Immunofluorescence confocal microscopy was performed with Olympus FV1000 MPE multiphoton laser scanning microscope (Olympus). Images were performed from three independent experiments and representative confocal micrograph images are presented.
Image Analysis
Confocal micrographs were analyzed using ImageJ software. For cytosolic versus junction detection comparisons, signal intensity was measured at indicated area from raw images, averaged, and plotted. Considering that the border staining for b-catenin strongly diminished nuclear detection, images were edited to highlight the areas of interest. For nuclear b-catenin presentation, nuclear areas were selected from DAPI image and then applied to b-catenin staining followed by removal of unselected area. A threshold was set to the resulting images to exclude background and Z-plotted for added clarity. Quantitative assessment of nuclear b-catenin detection was achieved by calculating the mean signal intensity with error bars representing standard error. Results are representative of three experiments.
Permeability Assay
Sodium fluorescein-flux assays were conducted as previously described [28] . Caco2 cells were plated on collagen I coated polycarbonate 12-well transwell inserts (0.4 lm pore size, Corning) and allowed to reach confluence. The luminal (upper) compartment was treated with sodium fluorescein (2.5 mg/mL) for 15 min; then, 100 lL aliquots were obtained from each abluminal (lower) compartment and assayed for fluorescence intensity. Permeability coefficients (P s ) were calculated using the formula 
Statistics
One-way ANOVA was used for data involving three or more groups with one variable followed by the Student's t test to determine significant difference between nontreated controls and indicated treatment group. Significance was noted at p \ 0.05 and noted with (*) to show significance relative to control or (¥) to indicate significance relative to IL-1b treatment in the absence of MLCK inhibitor (ML-7).
Results nmMLCK Inhibition Attenuated IL-1b-Induced Barrier Dysfunction of Caco2 Monolayers
Since nmMLCK inhibition had been shown previously to attenuate IL-1b-mediated barrier dysfunction, we aimed to determine whether this finding was also true for intestinal epithelial cells. Therefore, Caco2 barrier function was assayed via ECIS and permeability assays in the presence of vehicle control, IL-1b alone, or IL-1b with nmMLCK inhibitor (ML-7, 10 lM). As shown in Fig. 1a , IL-1b induced a decrease in TER (* 15 %) after treatment and did not return to baseline levels; however, the addition of ML-7 prevented the IL-1b drop in TER (Fig. 1a, b) . These findings are consistent with previous reports [2] .
Furthermore, permeability assays showed that sodium fluorescein (*0.38 kDa) accumulation resulting from IL-1b treatment was reduced by greater than threefold when cotreated with ML-7 (Fig. 1c) . These results suggest that nmMLCK plays a prominent role in IL-1b-induced barrier dysfunction of intestinal epithelial cells.
nmMLCK Inhibition Diminishes IL-1b-Mediated Decrease in Claudin-3 Expression
Since claudin-3 is a critical tight junction protein known to be downregulated in diseases involving increased permeability in intestinal epithelium, we hypothesized that tight junction protein expression may be downregulated in response to IL-1b treatment. Therefore, we treated Caco2 cells with IL-1b at different time points (0, 6, and 24 h) as well as different concentrations of IL-1b (10 or 100 ng/mL, 24 h) and assessed the expression of several tight junction proteins (occludin, ZO-1, claudin-1, claudin-2, claudin-3, claudin-4, claudin-15) expression by Western blot. Results showed that IL-1b (10 ng/mL) significantly reduced claudin-3 expression at 24 h (Fig. 2a) ; however, the other proteins showed no change in expression relative to treatment. Similarly, as shown in Fig. 2b , claudin-3 expression was reduced by approximately 40 % after 24 h of IL-1b treatment (10 ng/mL). However, 100 ng/mL IL-1b did not reduce claudin-3 expression significantly relative to the lower dose (Fig. 2b) . Next, considering nmMLCK inhibition attenuated IL-1b-driven claudin-5 downregulation [4] , we sought to determine whether nmMLCK inhibition rescued IL-1b-induced decrease in claudin-3 expression. Figure 2c shows that IL-1b alone reduced total claudin-3 expression by approximately 50 %, yet co-treatment of IL1b with ML-7 resulted in unperturbed claudin-3 expression despite the presence of IL-1b. Similar results were obtained when nmMLCK was targeted with siRNA (data not shown).
Inhibition of nmMLCK Restores Claudin-3 Expression at Cell-Cell Junctions
In subsequent experiments, we aimed to identify whether ML-7 improved claudin-3 expression specifically at cellcell borders when co-treated with IL-1b. Therefore, Caco2 cells were grown to confluence on coverslips, treated with either vehicle control, IL-1b or IL-1b ? ML-7, and assayed for claudin-3 detection at cell-cell borders via immunofluorescent microscopy. E-cadherin was stained to show cellcell border orientation. Results showed that ML-7 co-treatment with IL-1b indeed improved claudin-3 detection at cell-cell borders by over tenfold (Fig. 3b) compared to IL1b alone. Interestingly, E-cadherin detection at cell junctions was also improved with ML-7 treatment (Fig. 3c) , although not as robustly as claudin-3. Similarly, cytosolic detection of claudin-3 was approximately sixfold and E-cadherin cytosolic detection increased approximately fourfold upon treatment of IL-1b, yet inhibition of nmMLCK in the presence of IL-1b attenuated cytosolic detection down to control levels (Fig. 3d) . These results suggest that nmMLCK plays a role not only in IL-1b-induced downregulation of claudin-3, but also in its redistribution. 
Inhibition of nmMLCK Prevents Nuclear Accumulation of b-Catenin
Since it has been previously established that nmMLCK was required for IL-1b-induced nuclear translocation of b-catenin and subsequent repression of the claudin-5 promoter in endothelial cells [4] , we hypothesized that nmMLCK was also required for IL-1b-induced nuclear translocation of b-catenin in Caco2 cells. Therefore, Caco2 cells were grown to confluence and treated with IL-1b for 0, 1.5, 3, and 8 h, followed by nuclear fractionation and b-catenin detection by Western blot. As shown in the left panel of Fig. 4a , nuclear accumulation of b-catenin was robustly augmented after 3 h of IL-1b treatment relative to earlier time points. Subsequently, Caco2 cells were grown to confluence and treated with IL-1b (100 ng/mL) for 3 h either in the presence or absence of ML-7. These results showed that inhibition of nmMLCK greatly reduced IL1b-mediated nuclear translocation of b-catenin (Fig. 4a,  right panel) , which was confirmed in confocal image analysis (Fig. 4b, c) . As shown in Fig. 4c , nuclear detection of b-catenin increased by approximately threefold after 3 h of IL-1b treatment, but was diminished to control levels when co-treated with ML-7. These data suggest that nmMLCK signaling is involved in the nuclear translocation of b-catenin resulting from IL-1b in Caco2 cells.
nmMLCK Inhibition Prevents IL-1b-Induced bCatenin Targeting to the Claudin-3 Promoter
We next determined whether the nmMLCK-mediated downregulation of claudin-3 was due to transcriptional regulation by assaying claudin-3 mRNA after IL-1b treatment with or without nmMLCK inhibition with ML-7. As shown in Fig. 5a , IL-1b significantly decreased claudin-3 mRNA by roughly 80 %, and inhibition of nmMLCK attenuated transcriptional claudin-3 downregulation to control level of expression despite IL-1b treatment. Furthermore, ChIP experiments showed that IL-1b-induced b-catenin association with the claudin-3 promoter was reduced by approximately twofold when co-treated with b Fig. 2 nmMLCK mediates IL-1b-induced claudin-3 downregulation in Caco2 cells. a Caco2 cells were treated with 100 ng/nl IL-1b for 0, 6, or 24 h, or b with 0, 10, or 100 ng/mL for 24 h. Cell lysates were analyzed by Western blot and degree of claudin-3 expression was assessed by densitometry. b-Actin was probed as loading control. c Caco2 cells were treated with vehicle control or ML-7 (10 lM) followed by IL-1b treatment (10 or 100 ng/mL) and claudin-3 protein expression was assessed by Western blot. Results are representative of 3 experiments ML-7 (Fig. 5b, c) . These results suggest that nmMLCK plays a role in regulating claudin-3 expression at the level of transcription and that inhibition of nmMLCK prevents b-catenin targeting to the claudin-3 promoter.
Discussion
In this study, we used Caco2 cells to further characterize the signaling pathway for IL-1b-mediated epithelial permeability. The novel findings in this report are that (1) IL-1b induced claudin-3 downregulation in Caco2 cells, (2) IL-1b induced b-catenin targeting of the claudin-3 promoter in a manner involving nmMLCK, and (3) the IL-1b directed b-catenin targeting of the claudin-3 promoter was associated with repression of claudin-3. Although nmMLCK had been previously identified as being regulated by IL-1b [2, 13, 31] , we show that nmMLCK is involved in IL-1b-induced gene regulatory events that lead to downregulation of critical tight junction components in Caco2 cells. IL-1b-mediated epithelial permeability is characterized by several molecular pathways that occur in concert. The initial formation of stress fibers allows cellular contraction to ultimately form intercellular spaces [7] . Interestingly, the initial formation of central stress fibers contributes a temporary increase in resistance observed on ECIS due to actin polymerization and cell spreading and was indeed what was seen in our ECIS experiments in the initial 5 h following IL-1b treatment. Concomitantly, several posttranslational events lead to tyrosine phosphorylation, cellular contraction, and cytosolic translocation of junction proteins that possess dual function as transcription regulators (b-catenin, ZO-1, etc.). Indeed, our results indicated that IL-1b promoted b-catenin translocation to the nucleus at 3 h post-IL-1b treatment. We then sought to determine key junction proteins that demonstrated decreased expression in response to IL-1b that may be repressed by nuclear b-catenin. Since we previously demonstrated that b-catenin targeted a claudin promoter in a manner that repressed its expression in IL-1b-treated tight junction expressing cells, and nmMLCK regulates permeability in response to IL-1b, we hypothesized that a claudin protein may participate in a similar pathway in IL-1b-treated Caco2 cells. Therefore, we aimed to identify tight junction proteins that are significantly downregulated in response to IL-1b. Results showed IL-1b-mediated significant downregulation of claudin-3; however, expression levels of E-cadherin, ZO-1, occludin, claudin-1, claudin-4, or claudin-15 were unchanged between control and treated cells (data not shown). Although we showed that E-cadherin cytosolic accumulation was apparent after IL-1b, it has been shown that E-cadherin is not required for the maintenance of tight junctions, and its role in dynamic tight junction regulation is largely due to its b-catenin sequestering capacity [5, 27] . As Capaldo and others have shown, interruption of E-cadherin function in mature epithelial cells had little to no impact on barrier function, although impaired expression of E-cadherin did delay the development of new tight junctions as well as b-catenin detection at cell borders [5] . These findings support the idea that b-catenin sequestration at cellcell borders by association with E-cadherin ultimately leading to tight junction development (and corresponding claudin-3 expression) may act as an analogous mechanism to that observed with VE-cadherin in endothelial cells. Specifically, it has been shown that VE-cadherin regulates tight junction expression by sequestering b-catenin from transcriptional repression of the Cldn5 gene. Therefore, we interpret the observation that b-catenin targeted the claudin-3 promoter may serve as a contributing factor in IL-1b-mediated claudin-3 downregulation. Since the role of claudin-3 in intestinal epithelial permeability has been clearly shown in vitro and clinically [8, 16, 34] , claudin-3 downregulation and translocation from the tight junction also appear to be a significant factor contributing to the barrier dysfunction seen in IL-1b-treated Caco2 cells.
It has been previously established that nmMLCK plays a role in IL-1b-induced epithelial barrier dysfunction [2, 13, 31] . In the study conducted by Ma et al., IL-1b induced a dose-and time-dependent increase in nmMLCK protein expression at the level of mRNA and protein. Furthermore, inhibiting nmMLCK with siRNA improved TER changes induced by IL-1b, which is consistent with our findings. In addition, nmMLCK has been shown to have a direct role in modulating nuclear b-catenin accumulation in a manner that affects tight junction protein expression [4] . Specifically, primary cells isolated from nmMLCK knockout mice demonstrated attenuated nuclear accumulation of b-catenin and increased claudin-5 expression relative to IL-1b-treated wild-type cells. Consistent with this report, we show here that nmMLCK also plays a role in regulating claudin-3 expression in response to IL-1b in a manner that involves b-catenin targeting of the claudin-3 promoter. Importantly, these results suggest that nmMLCK modulates transcriptional activity in addition to regulating cytoskeletal contraction in Caco2 cells. Therefore, it appears that the involvement of nmMLCK in regulating b-catenin impacts the signaling and transcriptional functions of b catenin.
Another significant finding in this study was that IL-1b induced a direct association of b-catenin with the claudin-3 promoter in an nmMLCK-dependent manner. Consistent with these findings, other reports have shown that Wnt signaling (and subsequent b-catenin nuclear accumulation) induced Claudin-3 downregulation. [11] . In other reports, b-catenin-mediated downregulation of claudin-5 required b-catenin direct association and recruitment of FoxO1 with the claudin-5 promoter in order for claudin-5 downregulation to occur [4] . Since we observed direct association of b-catenin with the claudin-3 promoter, it is tempting to speculate that this mechanism of non-Wnt b-catenin signaling may also be driving IL-1b-mediated downregulation of claudin-3 in epithelial cells.
In summary, this report identifies a signaling role of nmMLCK in modulating epithelial barrier function in addition to its known role in regulating cytoskeletal contractility. These results support the idea that nmMLCK may serve as a suitable drug target in restoring barrier function in conditions involving inflammation-driven epithelial permeability in the gut.
